share_log

JP Morgan Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $202

Benzinga ·  Aug 19 21:14  · Ratings

JP Morgan analyst Jessica Fye maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $190 to $202.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment